MDxHealth vs Exagen
MDXH and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MDXH and XGN compare
MDxHealth grew revenue faster over the last twelve months (19.8% versus 13.7% for Exagen).
Exagen keeps more of each dollar of sales as profit, with a net margin of −25.1% compared with −31.1% at MDxHealth.
MDxHealth scores higher on the StockData Score (5 against 4 for Exagen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MDXH | XGN |
|---|---|---|
| Size and price | ||
| Market cap | – | $100M |
| Share price | $0.144 | $4.13 |
| Change, 1 year | −96.5% | −56.9% |
| Change, 5 years | −98.6% | −65.9% |
| Beta (5Y) | 0.97 | 1.18 |
| Employees | 364 | 220 |
| StockData Score | ||
| Total score | 5 (better) | 4 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 1 | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 1.4× |
| P/B | – | 7.3× |
| FCF yield | – | −13.0% |
| Fair value | – | $3.60 |
| Margin of safety | – | −14.7% |
| Growth | ||
| Revenue growth (TTM) | 19.8% (better) | 13.7% |
| Revenue growth, 5Y average | 42.3% (better) | 9.7% |
| Profitability | ||
| Gross margin | 64.5% (better) | 58.7% |
| Operating margin | −13.4% (better) | −20.1% |
| Net margin | −31.1% | −25.1% (better) |
| FCF margin | −3.1% (better) | −18.0% |
| Return on equity | – | −114% |
| Return on invested capital | – | −167% |
| Financial health | ||
| Debt / equity | – | 1.66 |
| Interest coverage | −0.6× (better) | −2.9× |
| Current ratio | 1.08 | 3.46 (better) |
| Altman Z-score | – | −5.71 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | – | 0.00% |
| Ownership | ||
| Held by institutions | 32.3% | 34.1% |
| Held by insiders | – | 29.2% |
| Insider net buying, 12 months | $991K (better) | −$22.9K |
| Short interest, % of float | – | 4.2% |
Go deeper
- MDXH stock overview
- MDXH income statement
- MDXH valuation and score
- XGN stock overview
- XGN income statement
- XGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.